The University of Basel has synthesized triazine derivatives acting as phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, neurological and immunological disorders.
Rhizen Pharmaceuticals SA and Incozen Therapeutics Pvt. Ltd. have disclosed salts of NAD+ ADP-ribosyltransferase poly [ADP-ribose] polymerase (PARP) inhibitors reported to be useful for the treatment of cancer, bone, cardiovascular, immunological, inflammatory and respiratory disorders, metabolic diseases and thrombosis.
Turnstone Biologics Corp. has received IND clearance from the FDA for the company's lead selected tumor-infiltrating lymphocyte (TIL) therapy program, TIDAL-01.
Researchers from Duality Biologics (Suzhou) Co. Ltd. presented preclinical data for a novel Trop-2-targeting antibody-drug conjugate (ADC), DB-1305, being developed for the treatment of solid tumors.
Researchers from the University of Zaragoza and Promontory Therapeutics Inc. have discovered that PT-112, which has a multimodal mechanism of action, could have different clinical applications in cancer treatment due to its effects on mitochondria in castration-resistant prostate cancer (CRPC). PT-112 is an immunogenic small molecule currently in phase II development in metastatic castration-resistant prostate cancer (mCRPC). The researchers designed PT-112 to target advanced solid tumors, such as thymus, small-cell, non-small-cell lung or CRPC.
Medipure Holdings Inc. has described cannabidiol (CBD) prodrugs reported to be useful for the treatment of pain, epilepsy, cancer, inflammation, psychosis and neurological, eye and immunological disorders.
Jacobio Pharmaceuticals Co. Ltd. has patented cellular tumor antigen p53 (TP53) (Tyr220Cys mutant) stabilizers reported to be useful for the treatment of cancer.
RSS
